Evaluating quality of life for patients treated with vectorized internal radiotherapy for neuroendocrine tumors.
Official title: Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.
Run by Hospices Civils de Lyon · NCT06043193 · Data updated 2026-11-12
This study is trying to see how vectorized internal radiotherapy affects the quality of life for patients with metastatic neuroendocrine tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 4 sites (Saint-Priest-en-Jarez, Saint-Etienne and 3 other locations) |
| Status | Recruiting |
| Started | February 20, 2024 |
| Main results expected | March 20, 2025 |
| Study ends | September 20, 2026 |
| Registry record updated | June 11, 2025 |
| Trial ID | NCT06043193 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who are starting treatment with vectorized internal radiotherapy for neuroendocrine tumors.
✕Probably not a fit
Patients who are incarcerated or under legal protection measures will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the quality of life and tolerance of patients undergoing vectorized internal radiotherapy (RIV) for metastatic neuroendocrine tumors. Participants will complete quality of life questionnaires at specified times during their treatment, utilizing a remote computerized data collection system to facilitate participation. Patients will create an account on a patient interface to streamline data extraction and receive automated reminders for questionnaire completion. The study focuses on gathering patient-reported outcomes to better understand the impact of RIV treatment.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the quality of life for patients undergoing RIV treatment, potentially leading to improved patient care and treatment protocols.
How similar studies have gone: While this approach is focused on quality of life assessments, similar studies have shown success in evaluating patient-reported outcomes in cancer treatments.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years; * Patient starting treatment with RIV validated in the RENATEN RCP; * Patient having received written information about the study; * Collection of the patient's non-objection * Patients for whom treatment with RIV is administered within the framework of a clinical trial, may be included in the AURARIV-TNE study according to the written indications written in the 2 nd protocol of the sponsor of the clinical trial; * Patients undergoing re-treatment with RIV can be included; Exclusion Criteria: * Persons deprived of their liberty by a judicial or administrative decision; * Adults subject to a legal protection measure (guardianship, curatorship);
Where it's running
-
CHU de Saint-Etienne, Hôpital Nord
Saint-Priest-en-Jarez, Saint-Etienne, France Recruiting -
CH Métropole Savoie
Chambéry, France Recruiting -
Centre de Lutte Contre le Cancer Jean Perrin
Clermont-Ferrand, France Recruiting -
Hospices Civils de Lyon, Hopital Lyon Sud
Lyon, France Recruiting
Study contacts
- Study coordinator: Nicolas JACQUET-FRANCILLON, MD
- Email: nicolas.jacquet-francillon@chu-lyon.fr
- Phone: 4 72 35 69 99
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood viscosity in ARDS: a look at how thick the blood is
This study tests whether blood viscosity is higher in adults with ARDS and whether viscosity relates to their breathing and blood flow issues.
-
Virus interactions in hospitalized patients during winter seasons in Lyon
This study tests all virological results from hospitalized patients in Lyon during winter to see how different respiratory viruses may co-occur or exclude each other.
-
Surgical Use of Efanoctocog alfa in Hemophilia A Patients
This observational study looks at how efanesoctocog alfa (Altuvoct) is used around surgery in people with hemophilia A to see if it helps control bleeding.
-
Sleep quality and its determinants during the liver transplant pathway
This study tests how sleep quality changes from before liver transplantation to six months after, in adults on the transplant waitlist at a single hospital.
-
Compare Trans-Stomal Bladder Lithotripsy Methods in Continent Catheterizable Urinary Reservoirs
This study looks at different ways to break up bladder stones in people with continent catheterizable urinary diversions to see which method works best when the normal route isn’t available.
-
French version validation of the New Mobility Score for older adults after hip fracture
This study tests whether the French version of the New Mobility Score accurately measures mobility in French patients aged 75 and older after hip fracture.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.